It could be used as peptide-based vaccine or cellular therapy, with the hope of controlling the residual disease after classical treatment or to decrease the risks of relapse. Poster No. 195 In vivo Targeting and Killing of Mouse Prostate Cancer Tissue with Vesicular Stomatitis Virus (VSV) Maryam Moussavi 1 , Ladan Fazli2, Howard Tearle2, Michael E. Cox2, John Bell3, Christopher Ong2, William Jia4, Paul Rennie2,5 1 Experimental Medicine, Vancouver Prostate Centre, Vancouver, BC, Canada, 2 The Vancouver Prostate Centre, Vancouver General Hospital, Vancouver, BC, Canada, 3 Centre for Cancer Therapeutics, Ottawa Health Research Institute,

Ottawa, ON, Canada, 4 Department of Surgery and Brain Research Centre, BI 10773 clinical trial University of British Columbia, Vancouver,

BC, Necrostatin-1 nmr Canada, 5 Department of Urological Science, University of British Columbia, Vancouver, BC, Canada Prostate cancer is the most commonly diagnosed non-skin carcinoma and one of the leading causes of cancer-related mortality of men in western society. Presently there are no therapies available for advance and metastatic prostate cancer. Oncolytic viral therapy may be used as a new and alternate therapy to current treatments and provides an GSK872 price opportunity to efficiently direct cell death to primary and metastatic cancer cells while sparing normal cells. Vesicular Stomatitis Virus (VSV) is an oncolytic virus which is able to replicate in cells with a defective interferon (INF) response. Here, we examined the effect of a mutated VSV (AV3 strain), which expresses luciferase and has an enhanced INF-sensitivity, on the viability of prostate tumours that

develop in prostate-specific PTEN null transgenic mice. Prostates of PTEN knockout and control mice were injected with 5×108 pfu/ml of VSV(AV3) and monitored for luminescence over a 96 h time period using the IVIS-Xenogen machine to track the viral distribution. Both real time qPCR and plaque analysis indicated viral presence P-type ATPase and replication in prostate tissues of PTEN null transgenic mice while little to no replication is seen in control mice. TUNEL analysis of paraffin embedded tissues demonstrated that VSV(AV3) is capable of selectively infecting and killing malignant prostate cells while sparing normal cells, specifically at the 48 h time point. This cancer-specific cell death was not due to infiltration of neutrophil into the prostate tumours of PTEN null mice as previously reported in an orthotropic mouse model. However, an increase in macrophage and B-lymphocyte infiltration into the prostates of PTEN null mice is seen when compared to control mice. In summary, our data demonstrates that VSV may be used as a potential oncolytic viral therapy to target prostate cancer. Poster No.